NCT04640480View on ClinicalTrials.gov

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Colorectal CancerBreast CancerPancreas CancerOvarian CancerSmall-cell Lung CancerGastric CancerHead and Neck Cancer
Interventions
DRUG

SNB-101

SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Trial Locations (3)

13496

CHA Medical Center, Seongnam-si

03722

The Severance Hospital of the Yonsei University, Seoul

06591

The Catholic University of Korea Seoul ST. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

SN BioScience
All Listed Sponsors
lead

SN BioScience

INDUSTRY

NCT04640480 - Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | Biotech Hunter | Biotech Hunter